SCHEMBL771311

SCHEMBL771311

O=C1c2cccc(O)c2C(=O)N1CCC(=O)N1CCCC2CCCCC21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
HSD17B10 Q99714 3/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770064 0.93 ALDH1A1 (0.45) ALDH1A1HPGDMAPK1SMN1; SMN2KDM4E
SCHEMBL770733 0.87 ALDH1A1 (0.58) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL771137 0.82 ACHE (0.46) ALDH1A1KMT2AHPGDMAPK1SMN1; SMN2
SCHEMBL770858 0.81 ACHE (0.60) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL15377479 0.80 ALDH1A1 (0.56) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL769924 0.78 DRD2 (0.45) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL770137 0.77 SMN1; SMN2 (0.47) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL771032 0.77 ALDH1A1 (0.43) ALDH1A1HSD17B10KMT2AGAAHPGD
SCHEMBL770403 0.77 DRD2 (0.44) ALDH1A1HSD17B10KMT2AHPGDSMN1; SMN2
SCHEMBL771729 0.76 SMN1; SMN2 (0.57) ALDH1A1HSD17B10KMT2AGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885HSD17B10 19/4885KMT2A 3868/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885HSD17B10 19/4885KMT2A 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.